<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">20610085</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1873-4502</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>36</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2010</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Journal of cataract and refractive surgery</Title>
<ISOAbbreviation>J Cataract Refract Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation.</ArticleTitle>
<Pagination>
<MedlinePgn>1095-100</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrs.2009.12.049</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the efficacy of cyclosporine 0.05% in alleviating dry-eye signs and improving visual quality after multifocal intraocular lens (IOL) implantation.</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">Private practice and university medical center, New York, New York, USA.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This randomized prospective contralaterally controlled double-masked trial comprised patients scheduled to have bilateral phacoemulsification with implantation of a refractive multifocal IOL (ReZoom). Patients received twice-daily cyclosporine 0.05% in 1 eye and an artificial tear in the other eye from 1 month before to 2 months after second-eye surgery. Outcomes were evaluated at baseline and 2 months after second-eye surgery.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The study enrolled 28 eyes of 14 patients. At baseline, there were no statistically significant between-group differences in outcome measures. Two months postoperatively, the cyclosporine group had significantly lower mean uncorrected distance visual acuity than the artificial tear group (0.11 logMAR +/- 0.03 [SD] [20/25 Snellen equivalent] versus 0.19 +/- 0.05 logMAR [20/30]; P = .045) as well as significantly lower mean corrected distance visual acuity (0.0 +/- 0.02 logMAR [20/20] versus 0.1 +/- 0.02 logMAR [20/25]; P = .005) and corneal staining scores (0.210 +/- 0.07 versus 0.645 +/- 0.18; P = .034). Treatment with cyclosporine 0.05% also improved contrast sensitivity, conjunctival staining, and tear breakup time. Significantly more patients preferred the eye treated with cyclosporine 0.05% to the eye treated with artificial tears (57.1% versus 14.3%; P = .007).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cyclosporine 0.05% therapy reduced dry-eye signs and improved visual quality after multifocal IOL implantation.</AbstractText>
<AbstractText Label="FINANCIAL DISCLOSURE" NlmCategory="BACKGROUND">No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes.</AbstractText>
<CopyrightInformation>Copyright 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Donnenfeld</LastName>
<ForeName>Eric D</ForeName>
<Initials>ED</Initials>
<AffiliationInfo>
<Affiliation>Ophthalmic Consultants of Long Island, 2000 North Village Avenue, Suite 402, Rockville Centre, New York 11570, USA. eddoph@aol.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Solomon</LastName>
<ForeName>Ren√©e</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roberts</LastName>
<ForeName>Calvin W</ForeName>
<Initials>CW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wittpenn</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McDonald</LastName>
<ForeName>Marguerite B</ForeName>
<Initials>MB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Perry</LastName>
<ForeName>Henry D</ForeName>
<Initials>HD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cataract Refract Surg</MedlineTA>
<NlmUniqueID>8604171</NlmUniqueID>
<ISSNLinking>0886-3350</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>83HN0GTJ6D</RegistryNumber>
<NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000287">Administration, Topical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015350">Contrast Sensitivity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016572">Cyclosporine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015352">Dry Eye Syndromes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019654">Lens Implantation, Intraocular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018918">Phacoemulsification</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014792">Visual Acuity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2009</Year>
<Month>08</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2009</Year>
<Month>12</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2009</Year>
<Month>12</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>8</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20610085</ArticleId>
<ArticleId IdType="pii">S0886-3350(10)00555-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.jcrs.2009.12.049</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>